Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: Utilization persists despite the boxed warning

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 6, 2015, Pages 647-653

  Kulik, Alexander ^a,b   Bykov, Katsiaryna ^a   Choudhry, Niteesh K ^a   Bateman, Brian T ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Analgesia; Coronary artery bypass graft (CABG); Pain; Pharmacoepidemiology; Postoperative care

Indexed keywords

IBUPROFEN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; ETODOLAC;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DRUG INDICATION; DRUG UTILIZATION; ERYTHROCYTE TRANSFUSION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART VALVE SURGERY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TEACHING HOSPITAL; TREATMENT DURATION; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; DRUG ADMINISTRATION; EPIDEMIOLOGY; FACTUAL DATABASE; PAIN, POSTOPERATIVE; POSTOPERATIVE CARE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CORONARY ARTERY BYPASS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; ETODOLAC; FEMALE; HUMANS; KETOROLAC; MALE; PAIN, POSTOPERATIVE; POSTOPERATIVE CARE; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 84930416711     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3788     Document Type: Article

References (22)

1. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007; 105: 205-21.
2. Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003; 97: 534-40.
3. Bainbridge D, Cheng DC, Martin JE, et al. NSAID-analgesia, pain control and morbidity in cardiothoracic surgery. Can J Anaesth 2006; 53: 46-59.
4. Kulik A, Ruel M, Bourke ME, et al. Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial. Eur J Cardiothorac Surg 2004; 26: 694-700.
5. FDA U.S. Food and Drug Administration (4 April 2005), Public Health Advisory-FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm Accessed October 19, 2012.
6. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-92.
7. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
8. Oliveri L, Jerzewski K, Kulik A. Black box warning: is ketorolac safe for use after cardiac surgery? J Cardiothorac Vasc Anesth 2014; 28: 274-9.
9. Engoren MC, Habib RH, Zacharias A, et al. Postoperative analgesia with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft surgery in patients already receiving aspirin: a propensity-matched study. J Cardiothorac Vasc Anesth 2007; 21: 820-6.
10. Engoren M, Hadaway J, Schwann TA, et al. Ketorolac improves graft patency after coronary artery bypass grafting: a propensity-matched analysis. Ann Thorac Surg 2011; 92: 603-9.
11. Kulik A, Rassen JA, Myers J, et al. Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. Circ Cardiovasc Interv 2012; 5: 590-6.
12. Kulik A, Brookhart MA, Levin R, et al. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008; 118: 1785-92.
13. Choiniere M, Watt-Watson J, Victor JC, et al. Prevalence of and risk factors for persistent postoperative nonanginal pain after cardiac surgery: a 2-year prospective multicentre study. CMAJ 2014; 186: E213-23.
14. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-11.
15. Piening S, Haaijer-Ruskamp FM, de Vries JT, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf 2012; 35: 373-85.
16. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65: 94-101.
17. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2: 155-63.
18. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
19. Litvak KM, McEvoy GK. Ketorolac, an injectable nonnarcotic analgesic. Clin Pharm 1990; 9: 921-35.
20. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53: 139-88.
21. Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol 2000; 22: 291-8.
22. Lee A, Cooper MC, Craig JC, et al. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Database Syst Rev 2004: CD002765.